272 related articles for article (PubMed ID: 34208765)
1. Dynamic Evaluation of Circulating miRNA Profile in
Leonetti A; Capula M; Minari R; Mazzaschi G; Gregori A; El Hassouni B; Papini F; Bordi P; Verzè M; Avan A; Tiseo M; Giovannetti E
Cells; 2021 Jun; 10(6):. PubMed ID: 34208765
[TBL] [Abstract][Full Text] [Related]
2. Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation.
Wang S; Su X; Bai H; Zhao J; Duan J; An T; Zhuo M; Wang Z; Wu M; Li Z; Zhu J; Wang J
J Hematol Oncol; 2015 Nov; 8():127. PubMed ID: 26563758
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
[TBL] [Abstract][Full Text] [Related]
4. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
Park KS; Raffeld M; Moon YW; Xi L; Bianco C; Pham T; Lee LC; Mitsudomi T; Yatabe Y; Okamoto I; Subramaniam D; Mok T; Rosell R; Luo J; Salomon DS; Wang Y; Giaccone G
J Clin Invest; 2014 Jul; 124(7):3003-15. PubMed ID: 24911146
[TBL] [Abstract][Full Text] [Related]
5. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population.
Sutandyo N; Hanafi A; Jayusman M
Zhongguo Fei Ai Za Zhi; 2019 Sep; 22(9):562-567. PubMed ID: 31526459
[TBL] [Abstract][Full Text] [Related]
7. Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients.
Hojbjerg JA; Ebert EBF; Clement MS; Winther-Larsen A; Meldgaard P; Sorensen B
Lung Cancer; 2019 Sep; 135():92-96. PubMed ID: 31447008
[TBL] [Abstract][Full Text] [Related]
8. Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort.
Lau SC; Chooback N; Ho C; Melosky B
Clin Lung Cancer; 2019 Sep; 20(5):e576-e583. PubMed ID: 31178389
[TBL] [Abstract][Full Text] [Related]
9. Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib.
Takeda M; Okamoto I; Nakagawa K
J Thorac Oncol; 2014 Feb; 9(2):200-4. PubMed ID: 24419417
[TBL] [Abstract][Full Text] [Related]
10. REPORT- Clinical outcomes of using second - versus first-Generation EGFR-tkis for the First-Line treatment of advanced NSCLC patients with EGFR mutations: A meta-analysis.
Hou B; Lu X; Gao DC; Liu QX; Zhou D; Zheng H; Dai JG
Pak J Pharm Sci; 2021 Jul; 34(4):1459-1468. PubMed ID: 34799322
[TBL] [Abstract][Full Text] [Related]
11. The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients.
Szpechcinski A; Florczuk M; Duk K; Zdral A; Rudzinski S; Bryl M; Czyzewicz G; Rudzinski P; Kupis W; Wojda E; Giedronowicz D; Langfort R; Barinow-Wojewodzki A; Orlowski T; Chorostowska-Wynimko J
Cell Mol Life Sci; 2019 Sep; 76(18):3641-3656. PubMed ID: 30953094
[TBL] [Abstract][Full Text] [Related]
12. Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study.
Miyawaki T; Kenmotsu H; Kodama H; Nishioka N; Miyawaki E; Mamesaya N; Kobayashi H; Omori S; Ko R; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Harada H; Endo M; Takahashi K; Takahashi T
BMC Cancer; 2021 Nov; 21(1):1247. PubMed ID: 34798865
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations.
Arrieta O; Catalán R; Guzmán-Vazquez S; Barrón F; Lara-Mejía L; Soto-Molina H; Ramos-Ramírez M; Flores-Estrada D; de la Garza J
BMC Cancer; 2020 Sep; 20(1):829. PubMed ID: 32873256
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions.
Leonetti A; Assaraf YG; Veltsista PD; El Hassouni B; Tiseo M; Giovannetti E
Drug Resist Updat; 2019 Jan; 42():1-11. PubMed ID: 30544036
[TBL] [Abstract][Full Text] [Related]
15. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
16. Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan.
Hsieh YY; Fang WT; Lo YW; Chen YH; Chien LN
Int J Cancer; 2020 Aug; 147(4):1107-1116. PubMed ID: 31854456
[TBL] [Abstract][Full Text] [Related]
17. Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.
Schuler M; Fischer JR; Grohé C; Gütz S; Thomas M; Kimmich M; Schneider CP; Laack E; Märten A;
Oncologist; 2014 Oct; 19(10):1100-9. PubMed ID: 25232040
[TBL] [Abstract][Full Text] [Related]
18. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ
BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564
[TBL] [Abstract][Full Text] [Related]
19. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
Ge P; Cao L; Chen X; Jing R; Yue W
BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
[TBL] [Abstract][Full Text] [Related]
20. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in
Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]